Douglas Swirsky was named Chief Financial Officer of Barinthus Biotherapeutics plc., effective May 1, 2026. As of November 6, 2026, Barinthus Biotherapeutics plc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 31, 2026 to April 22, 2026, naming 1 appointment (Form 8-K, April 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Barinthus Biotherapeutics plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Barinthus Biotherapeutics plc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-31 to 2026-04-22. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Barinthus Biotherapeutics plc. files it.
Also on the record for Barinthus Biotherapeutics plc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 11, 2026 | Stake report, Schedule 13G/A, by Oxford Science Enterprises plc | — | 5%+ stakes | Source |
| September 9, 2026 | Acquired by Beacon Topco, Inc. | — | Acquisition | Source |
| April 13, 2026 | Stake report, Schedule 13D, by International Generosity Foundation Trust | 6.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Barinthus Biotherapeutics plc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Barinthus Biotherapeutics plc. and the records around it.
Barinthus Biotherapeutics plc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Acquisition Sep 2026
Companies that share a holder
- Oxford Science Enterprises plc also filed stake reports on 1 other company: PepGen Inc. (Oct 2025)
Watch Barinthus Biotherapeutics plc.
Get an email when Barinthus Biotherapeutics plc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Barinthus Biotherapeutics plc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Barinthus Biotherapeutics plc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Barinthus Biotherapeutics plc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-22 | In | Chief Financial Officer | 2026-05-01 | 8-K, 2026-04-22 | |
| 2026-03-31 | Reported | not named in the filing | 8-K, 2026-03-31 |
Who leads Barinthus Biotherapeutics plc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Douglas Swirsky, appointed, effective 2026-05-01 (filed 2026-04-22).
New leaders reset buying decisions — get the Full Report on Barinthus Biotherapeutics plc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Barinthus Biotherapeutics plc., with the record behind each one.
Find candidates like Chief Financial Officer at Barinthus Biotherapeutics plc.Every change, in the filing's words
Appointed: Douglas Swirsky, Chief Financial Officer, effective 2026-05-01
On April 22, 2026, the board of directors of Barinthus Biotherapeutics plc (the "Company") appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer of the Company, effective as of May 1, 2026 (the "Appointment").
- Douglas Swirsky, age 56, has over 25 years of experience in a wide range of industries.
- Mr. Swirsky served as Chief Financial Officer of MaxCyte, Inc. from March 2023 to March 2026 and currently is a Senior Advisor to MaxCyte's Chief Executive Officer.
- Prior to that, Mr. Swirsky served as Chief Financial Officer and Treasurer of AavantiBio, Inc. from February 2021 until its acquisition by Solid Biosciences, Inc. in December 2022.
- Before that, Mr. Swirsky served as President, Chief Executive Officer and a director of Rexahn Pharmaceuticals, Inc. from November 2018 until November 2020.
- Mr. Swirsky currently serves as chairman of the board of directors of Cellectar Biosciences, Inc. Previously, he also served on the board of directors of NeuroBo Pharmaceuticals, Inc. Mr. Swirsky is a certified public accountant in the state of Maryland and a CFA charterholder.
- He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University.
- In connection with the Appointment, the Company entered into a master services agreement (the "MSA") with Grand Strand BioAdvisors LLC, pursuant to which Mr. Swirsky, as a Managing Member of Grand Strand BioAdvisors LLC, will provide services to the Company as Chief Financial Officer and principal accounting officer.
Reported
On March 27, 2026, Ms. Jones notified the Company that she will step down as the Company's principal accounting officer, effective as of April 30, 2026.
- As previously disclosed, Gemma Jones provides services to Barinthus Biotherapeutics plc (the "Company") as an employee of CFGI and serves as the Company's principal accounting officer.
Tools for this story
Each opens in a new tab, filled in for Barinthus Biotherapeutics plc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.